INO-3107 · Voceryq
Gene therapy / editing
Evidence outlook
Approved: Recurrent Respiratory Papillomatosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04398433 NCT04398433 · Recurrent Respiratory Papillomatosis The study was open-label, non-randomized, and had no placebo or active comparator, with 32 participants. Its primary endpoint was safety rather than a controlled measure of treatment benefit, so the reported findings cannot establish that INO-3107 caused the observed changes in disease or surgery frequency. Registry: NCT04398433 | 1/2 | Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug through 30 days following the last dose (approximately up to Week 13)) 2022-12-15 | Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug through 30 days following the last dose (approximately up to Week 13)): INO-3107: Group 1 — Percentage of Participants with TEAEs: 33.3 percentage of participants; Percentage of Participants with Serious TEAEs: 0 percentage of participants | INO-3107: Group 2 — Percentage of Participants with TEAEs: 66.7 percentage of participants; Percentage of Participants with Serious TEAEs: 0 percentage of participants | INO-3107: Group 3 — Percentage of Participants with TEAEs: 75 percentage of participants; Percentage of Participants with Serious TEAEs: 12.5 percentage of participants | INO-3107 Overall — Percentage of Participants with TEAEs: 62.5 percentage of participants; Percentage of Participants with Serious TEAEs: 3.1 percentage of participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Recurrent Respiratory Papillomatosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| INO-3107 (Voceryq): this drug | Approved | Gene therapy / editing | HPV-6 and HPV-11 antigens | Weak signal | Featured results are safety only in this race | |
| Zopapogene Imadenovec (Papzimeos) | Approved | Gene therapy / editing | HPV6/HPV11 antigens (immunotherapy) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent